Literature DB >> 2559900

Use of simian immunodeficiency viruses for AIDS research.

R C Desrosiers1, D J Ringler.   

Abstract

Despite frequent statements to the contrary, there are good animal models for AIDS. In this review, we summarize the properties of one of the most useful animal models: infection of rhesus monkeys with simian immunodeficiency virus (SIV). The SIVs are an extensive group of HIV-related lentiviruses of nonhuman primates. They closely resemble the human AIDS viruses, HIV-1 and HIV-2, in both genetic sequence and biological properties. Some SIV isolates, most notably those derived from macaques and mangabeys, induce AIDS in rhesus monkeys in a time frame suitable for laboratory investigation. Rhesus monkeys are not endangered in the wild, they breed well in captivity, and they are available in reasonably large numbers. Study of SIV has already resulted in seminal contributions regarding the origins of the HIVs, AIDS pathogenesis, and vaccine and therapy research. Continued use of SIV systems will be an important weapon in our arsenal against AIDS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559900     DOI: 10.1159/000150108

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  23 in total

1.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease.

Authors:  Marie-Chantal Simard; Pavel Chrobak; Denis G Kay; Zaher Hanna; Serge Jothy; Paul Jolicoeur
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Immunodeficiency in the absence of high viral load in pig-tailed macaques infected with Simian immunodeficiency virus SIVsun or SIVlhoest.

Authors:  Brigitte E Beer; Charles R Brown; Sonya Whitted; Simoy Goldstein; Robert Goeken; Ronald Plishka; Alicia Buckler-White; Vanessa M Hirsch
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors:  E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

Review 5.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Complex determinants of macrophage tropism in env of simian immunodeficiency virus.

Authors:  K Mori; D J Ringler; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry.

Authors:  K Mori; D J Ringler; R C Desrosiers
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Cytokine influence on simian immunodeficiency virus replication within primary macrophages. TNF-alpha, but not GMCSF, enhances viral replication on a per-cell basis.

Authors:  D G Walsh; C J Horvath; A Hansen-Moosa; J J MacKey; P K Sehgal; M D Daniel; R C Desrosiers; D J Ringler
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

10.  Intrathecal humoral responses are inversely associated with the frequency of simian immunodeficiency virus macrophage-tropic variants in the central nervous system.

Authors:  Elena Ryzhova; Pyone Aye; Tom Harvey; Wei Cao; Andrew Lackner; Francisco González-Scarano
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.